Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACYW135 Meningococcal Conjugate Vaccine (CRM197)
- Development stage
- Unknown
- Lead developer
- Liaoning Chengda Biotechnology
- Modality
- Vaccines & Immunotherapeutics
01
Overview
ACYW135 Meningococcal Conjugate Vaccine (CRM197) is an investigational quadrivalent meningococcal conjugate vaccine being developed by Liaoning Chengda Biotechnology and affiliated Chengda entities for prevention of meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. It uses CRM197, a non-toxic diphtheria toxin variant, as a carrier protein for meningococcal capsular polysaccharide antigens, with the intended effect of inducing serogroup-specific bactericidal antibody responses and immunologic memory. In the Chengda-sponsored CTR20252317 study, the vaccine is being evaluated for safety and immunogenicity in healthy participants aged 3 months and older.
- Other names
- Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on ACYW135 Meningococcal Conjugate Vaccine (CRM197).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACYW135 Meningococcal Conjugate Vaccine (CRM197).